1. Maccioni RB, Muñoz JP, Barbeito L (2001) The molecular bases of Alzheimer’s disease and other neurodegenerative disorders. Archives of Medical Research 32:367–381 https://doi.org/10.1016/s0188-4409(01)00316-2
2. Di Domenico F, Sultana R, Barone E, et al (2011) Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer’s disease subjects. Journal of Proteomics 74:1091–1103. https://doi.org/10.1016/j.jprot.2011.03.033
3. Nagarathinam A, Höflinger P, Bühler A, et al (2013) Membrane-anchored Aβ accelerates amyloid formation and exacerbates amyloid-associated toxicity in mice. The Journal of neuroscience : the official journal of the Society for Neuroscience 33:19284–19294. https://doi.org/10.1523/JNEUROSCI.2542-13.2013
4. Vitiello G, Di Marino S, D’Ursi AM, D’Errico G (2013) Omega-3 fatty acids regulate the interaction of the Alzheimer’s aβ(25-35) peptide with lipid membranes. Langmuir : the ACS journal of surfaces and colloids 29:14239–14245. https://doi.org/10.1021/la403416b
5. González-Domínguez R, García-Barrera T, Gómez-Ariza JL (2014) Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer’s disease. Journal of Proteomics 104:37–47. https://doi.org/10.1016/j.jprot.2014.01.014
6. Falomir-Lockhart LJ, Cavazzutti GF, Giménez E, Toscani AM (2019) Fatty Acid Signaling Mechanisms in Neural Cells: Fatty Acid Receptors. Frontiers in cellular neuroscience 13:162. https://doi.org/10.3389/fncel.2019.00162
7. Bascoul-Colombo C, Guschina IA, Maskrey BH, et al (2016) Dietary DHA supplementation causes selective changes in phospholipids from different brain regions in both wild type mice and the Tg2576 mouse model of Alzheimer’s disease. Biochimica et biophysica acta 1861:524–537. https://doi.org/10.1016/j.bbalip.2016.03.005
8. Fonteh AN, Chiang AJ, Arakaki X, et al (2020) Accumulation of Cerebrospinal Fluid Glycerophospholipids and Sphingolipids in Cognitively Healthy Participants With Alzheimer’s Biomarkers Precedes Lipolysis in the Dementia Stage. Frontiers in neuroscience 14:611393. https://doi.org/10.3389/fnins.2020.611393
9. Shimohama S, Fujimoto S, Tresser N, et al (1993) Aberrant Phosphoinositide Metabolism in Alzheimer’s Disease. Annals of the New York Academy of Sciences 695:46–49. https://doi.org/10.1111/j.1749-6632.1993.tb23025.x
10. Canale C, Seghezza S, Vilasi S, et al (2013) Different effects of Alzheimer’s peptide Aβ(1-40) oligomers and fibrils on supported lipid membranes. Biophysical chemistry 182:23–29. https://doi.org/10.1016/j.bpc.2013.07.010
11. Svennerholm L, Gottfries CG (1994) Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). Journal of neurochemistry 62:1039–1047. https://doi.org/10.1046/j.1471-4159.1994.62031039.x
12. Akiyama H, Barger S, Barnum S, et al (2000) Inflammation and Alzheimer’s disease. Neurobiology of Aging 21:383–421. https://doi.org/10.1016/s0197-4580(00)00124-x.
13. Baron R, Babcock AA, Nemirovsky A, et al (2014) Accelerated microglial pathology is associated with Aβ plaques in mouse models of Alzheimer’s disease. Aging Cell 13:584–595. https://doi.org/10.1111/acel.12210
14. Nichols MR, St-Pierre MK, Wendeln AC, et al (2019) Inflammatory mechanisms in neurodegeneration. Journal of Neurochemistry 149:562–581. https://doi.org/10.1111/jnc.14674
15. Tran TTT, Corsini S, Kellingray L, et al (2019) APOE genotype influences the gut microbiome structure and function in humans and mice: relevance for Alzheimer’s disease pathophysiology. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 33:8221–8231. https://doi.org/10.1096/fj.201900071R
16. Uauy R, Mena P (2001) Lipids and neurodevelopment. In: Nutrition Reviews. International Life Sciences Institute, pp S34–S48. https://doi.org/10.1111/j.1753-4887.2001.tb05500.x
17. Martín V, Fabelo N, Santpere G, et al (2010) Lipid alterations in lipid rafts from Alzheimer’s disease human brain cortex. Journal of Alzheimer’s disease : JAD 19:489–502. https://doi.org/10.3233/JAD-2010-1242
18. Wong MW, Braidy N, Poljak A, et al (2017) Dysregulation of lipids in Alzheimer’s disease and their role as potential biomarkers. Alzheimer’s and Dementia 13:810–827. https://doi.org/10.1016/j.jalz.2017.01.008.
19. Chew H, Solomon VA, Fonteh AN (2020) Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies. Frontiers in physiology 11:598. https://doi.org/10.3389/fphys.2020.00598
20. Bazan NG (2005) Lipid signaling in neural plasticity, brain repair, and neuroprotection. Molecular Neurobiology 32:89–103. https://doi.org/10.1385/MN:32:1:089.
21. Adibhatla RM, Hatcher JF (2007) Role of Lipids in Brain Injury and Diseases. Future lipidology 2:403–422. https://doi.org/10.2217/17460875.2.4.403
22. Yamashima T, Ota T, Mizukoshi E, et al (2020) Intake of ω-6 Polyunsaturated Fatty Acid-Rich Vegetable Oils and Risk of Lifestyle Diseases. Advances in Nutrition 11:1489–1509. https://doi.org/10.1093/advances/nmaa072.
23. Isacson O, Brekk OR, Hallett PJ (2019) Novel Results and Concepts Emerging From Lipid Cell Biology Relevant to Degenerative Brain Aging and Disease. Frontiers in neurology 10:1053. https://doi.org/10.3389/fneur.2019.01053
24. Marinissen MJ, Gutkind JS (2001) G-protein-coupled receptors and signaling networks: Emerging paradigms. Trends in Pharmacological Sciences 22:368–376. https://doi.org/10.1016/s0165-6147(00)01678-3.
25. Zamarbide M, Etayo-Labiano I, Ricobaraza A, et al (2014) GPR40 activation leads to CREB and ERK phosphorylation in primary cultures of neurons from the mouse CNS and in human neuroblastoma cells. Hippocampus 24:733–739. https://doi.org/10.1002/hipo.22263
26. Nakamura MT, Yudell BE, Loor JJ (2014) Regulation of energy metabolism by long-chain fatty acids. Progress in lipid research 53:124–144. https://doi.org/10.1016/j.plipres.2013.12.001
27. Chitre NM, Moniri NH, Murnane KS (2019) Omega-3 Fatty Acids as Druggable Therapeutics for Neurodegenerative Disorders. CNS & Neurological Disorders - Drug Targets 18:735–749. https://doi.org/10.2174/1871527318666191114093749
28. Alexander SPH, Christopoulos A, Davenport AP, et al (2019) THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology 176:S21–S141. https://doi.org/10.1111/bph.14748
29. Stoddart LA, Smith NJ, Milligan G (2008) International union of pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: Pharmacology and pathophysiological functions. Pharmacological Reviews 60:405–417. https://doi.org/10.1124/pr.108.00802
30. Tikhonova IG (2017) Application of GPCR structures for modelling of free fatty acid receptors. In: Handbook of Experimental Pharmacology. Springer New York LLC, pp 57–77. https://doi.org/10.1007/164_2016_52.
31. Alexander SPH, Christopoulos A, Davenport AP, et al (2019) THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology 176:S21–S141. https://doi.org/10.1111/bph.14748
32. Le Poul E, Loison C, Struyf S, et al (2003) Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. Journal of Biological Chemistry 278:25481–25489. https://doi.org/10.1074/jbc.M301403200
33. Alvarez-Curto E, Milligan G (2016) Metabolism meets immunity: The role of free fatty acid receptors in the immune system. Biochemical pharmacology 114:3–13. https://doi.org/10.1016/j.bcp.2016.03.017
34. Feng X-T, Leng J, Xie Z, et al (2012) GPR40: a therapeutic target for mediating insulin secretion (review). International journal of molecular medicine 30:1261–1266. https://doi.org/10.3892/ijmm.2012.1142
35. Hudson BD, Smith NJ, Milligan G (2011) Experimental Challenges to Targeting Poorly Characterized GPCRs. Uncovering the Therapeutic Potential for Free Fatty Acid Receptors. In: Advances in Pharmacology. Academic Press Inc., pp 175–218. https://doi.org/10.1016/B978-0-12-385952-5.00006-3
36. Hara T, Kimura I, Inoue D, et al (2013) Free fatty acid receptors and their role in regulation of energy metabolism. Reviews of Physiology, Biochemistry and Pharmacology 164:77–116. https://doi.org/10.1007/112_2013_13
37. Poitout V (2018) Fatty Acids and Insulin Secretion: From FFAR and Near? Diabetes 67:1932–1934. https://doi.org/10.2337/dbi18-0027
38. Miletta MC, Petkovic V, Eblé A, et al (2014) Butyrate increases intracellular calcium levels and enhances growth hormone release from rat anterior pituitary cells via the G-protein-coupled receptors GPR41 and 43. PLoS ONE 9:. https://doi.org/10.1371/journal.pone.0107388
39. Yang Y, Tian X, Xu D, et al (2018) GPR40 modulates epileptic seizure and NMDA receptor function. Science advances 4:eaau2357. https://doi.org/10.1126/sciadv.aau2357
40. Karki P, Kurihara T, Nakamachi T, et al (2015) Attenuation of inflammatory and neuropathic pain behaviors in mice through activation of free fatty acid receptor GPR40. Molecular pain 11:6. https://doi.org/10.1186/s12990-015-0003-8
41. Lonsdale J, Thomas J, Salvatore M, et al (2013) The Genotype-Tissue Expression (GTEx) project. Nature Genetics 45:580–585. https://doi.org/10.1038/ng.2653
42. Nøhr MK, Egerod KL, Christiansen SH, et al (2015) Expression of the short chain fatty acid receptor GPR41/FFAR3 in autonomic and somatic sensory ganglia. Neuroscience 290:126–137. https://doi.org/10.1016/j.neuroscience.2015.01.040
43. Kimura I, Inoue D, Maeda T, et al (2011) Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proceedings of the National Academy of Sciences of the United States of America 108:8030–8035. https://doi.org/10.1073/pnas.1016088108
44. Mayer EA (2011) Gut feelings: the emerging biology of gut-brain communication. Nature reviews Neuroscience 12:453–466. https://doi.org/10.1038/nrn3071
45. Hoyles L, Jiménez-Pranteda ML, Chilloux J, et al (2018) Metabolic retroconversion of trimethylamine N-oxide and the gut microbiota. Microbiome 6:73. https://doi.org/10.1186/s40168-018-0461-0
46. van de Wouw M, Boehme M, Lyte JM, et al (2018) Short-chain fatty acids: microbial metabolites that alleviate stress-induced brain–gut axis alterations. Journal of Physiology 596:4923–4944. https://doi.org/10.1113/JP276431
47. Hou Y fang, Shan C, Zhuang S yue, et al (2021) Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson’s disease. Microbiome 9:. https://doi.org/10.1186/s40168-020-00988-6
48. Hsiao K, Chapman P, Nilsen S, et al (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (New York, NY) 274:99–102. https://doi.org/10.1126/science.274.5284.99
49. Samuel BS, Shaito A, Motoike T, et al (2008) Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proceedings of the National Academy of Sciences of the United States of America 105:16767–16772. https://doi.org/10.1073/pnas.0808567105
50. Zamarbide M, Gil-Bea FJ, Bannenberg P, et al (2018) Maternal imprinting on cognition markers of wild type and transgenic Alzheimer’s disease model mice. Scientific reports 8:6434. https://doi.org/10.1038/s41598-018-24710-7
51. Cuadrado-Tejedor M, Hervias I, Ricobaraza A, et al (2011) Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer’s disease. British Journal of Pharmacology 164:2029–2041. https://doi.org/10.1111/j.1476-5381.2011.01517.x
52. Dunah AW, Wang Y, Yasuda RP, et al (2000) Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson’s disease. Molecular Pharmacology 57:342–352.
53. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680–685. https://doi.org/10.1038/227680a0
54. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 162:156–159. https://doi.org/10.1016/0003-2697(87)90021-2
55. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica 82:239–59. https://doi.org/10.1007/BF00308809.
56. Zhang L, Lu W, Chen L, et al (2013) The early changes in behavior and the myelinated fibers of the white matter in the Tg2576 transgenic mouse model of Alzheimer’s disease. Neuroscience letters 555:112–117. https://doi.org/10.1016/j.neulet.2013.09.030
57. Avila J, Perry G (2021) A Multilevel View of the Development of Alzheimer’s Disease. Neuroscience 457:283–293. https://doi.org/10.1016/j.neuroscience.2020.11.015.
58. Rabbito A, Dulewicz M, Kulczyńska-Przybik A, Mroczko B (2020) Biochemical Markers in Alzheimer’s Disease. International journal of molecular sciences 21:. https://doi.org/10.3390/ijms21061989
59. Stoiljkovic M, Horvath TL, Hajós M (2021) Therapy for Alzheimer’s disease: Missing targets and functional markers? Ageing Research Reviews 68:101318. https://doi.org/10.1016/j.arr.2021.101318
60. Fonteh AN, Chiang AJ, Arakaki X, et al (2020) Accumulation of Cerebrospinal Fluid Glycerophospholipids and Sphingolipids in Cognitively Healthy Participants With Alzheimer’s Biomarkers Precedes Lipolysis in the Dementia Stage. Frontiers in neuroscience 14:611393. https://doi.org/10.3389/fnins.2020.611393
61. Zhang X, Liu W, Zan J, et al (2020) Untargeted lipidomics reveals progression of early Alzheimer’s disease in APP/PS1 transgenic mice. Scientific reports 10:14509. https://doi.org/10.1038/s41598-020-71510-z
62. Brown AJ, Goldsworthy SM, Barnes AA, et al (2003) The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. Journal of Biological Chemistry 278:11312–11319. https://doi.org/10.1074/jbc.M211609200
63. Le Poul E, Loison C, Struyf S, et al (2003) Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. Journal of Biological Chemistry 278:25481–25489. https://doi.org/10.1074/jbc.M301403200
64. Couto MR, Gonçalves P, Magro F, Martel F (2020) Microbiota-derived butyrate regulates intestinal inflammation: Focus on inflammatory bowel disease. Pharmacological Research 159. https://doi.org/10.1016/j.phrs.2020.104947.
65. Kimura I, Ichimura A, Ohue-Kitano R, Igarashi M (2020) Free Fatty Acid Receptors in Health and Disease. Physiological reviews 100:171–210. https://doi.org/10.1152/physrev.00041.2018
66. Wolf A, Bauer B, Abner EL, et al (2016) A Comprehensive Behavioral Test Battery to Assess Learning and Memory in 129S6/Tg2576 Mice. PloS one 11:e0147733. https://doi.org/10.1371/journal.pone.0147733
67. Kim HJ, Chang K-A, Ha T-Y, et al (2014) S100A9 knockout decreases the memory impairment and neuropathology in crossbreed mice of Tg2576 and S100A9 knockout mice model. PloS one 9:e88924. https://doi.org/10.1371/journal.pone.0088924
68. Lanahan A, Worley P (1998) Immediate-early genes and synaptic function. In: Neurobiology of Learning and Memory. Academic Press Inc., pp 37–43. https://doi.org/10.1006/nlme.1998.3836.
69. Guzowski JF (2002) Insights into immediate-early gene function in hippocampal memory consolidation using antisense oligonucleotide and fluorescent imaging approaches. Hippocampus 12:86–104. https://doi.org/10.1002/hipo.10010
70. Christensen DZ, Thomsen MS, Mikkelsen JD (2013) Reduced basal and novelty-induced levels of activity-regulated cytoskeleton associated protein (Arc) and c-Fos mRNA in the cerebral cortex and hippocampus of APPswe/PS1ΔE9 transgenic mice. Neurochemistry international 63:54–60. https://doi.org/10.1016/j.neuint.2013.04.002
71. Sierksma ASR, Van Den Hove DLA, Pfau F, et al (2014) Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D. Neuropharmacology 77:120–130. https://doi.org/10.1016/j.neuropharm.2013.09.015
72. Palop JJ, Chin J, Bien-Ly N, et al (2005) Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice. Journal of Neuroscience 25:9686–9693. https://doi.org/10.1523/JNEUROSCI.2829-05.2005
73. Zamarbide M, Etayo-Labiano I, Ricobaraza A, et al (2014) GPR40 activation leads to CREB and ERK phosphorylation in primary cultures of neurons from the mouse CNS and in human neuroblastoma cells. Hippocampus 24:733–739. https://doi.org/10.1002/hipo.22263
74. Reese LC, Laezza F, Woltjer R, Taglialatela G (2011) Dysregulated phosphorylation of Ca 2+/calmodulin-dependent protein kinase II-α in the hippocampus of subjects with mild cognitive impairment and Alzheimer’s disease. Journal of Neurochemistry 119:791–804. https://doi.org/10.1111/j.1471-4159.2011.07447.x
75. Almeida CG, Tampellini D, Takahashi RH, et al (2005) Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiology of disease 20:187–198. https://doi.org/10.1016/j.nbd.2005.02.008
76. Gylys KH, Fein JA, Yang F, et al (2004) Snaptic changes in alzheimer’s disease: Increased amyloid-β and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. American Journal of Pathology 165:1809–1817. https://doi.org/10.1016/s0002-9440(10)63436-0
77. Tao X, Finkbeiner S, Arnold DB, et al (1998) Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20:709–726. https://doi.org/10.1016/s0896-6273(00)81010-7
78. Seidah NG, Chrétien M (1999) Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain research 848:45–62. https://doi.org/10.1016/s0006-8993(99)01909-5
79. Bibel M, Barde YA (2000) Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes & development 14:2919–2937. https://doi.org/10.1101/gad.841400
80. Schindowski K, Belarbi K, Buée L (2008) Neurotrophic factors in Alzheimer’s disease: Role of axonal transport. In: Genes, Brain and Behavior. Blackwell Publishing Ltd, pp 43–56. https://doi.org/10.1111/j.1601-183X.2007.00378.x.
81. O’Bryant SE, Hobson V, Hall JR, et al (2009) Brain-derived neurotrophic factor levels in alzheimer’s disease. Journal of Alzheimer’s Disease 17:337–341. https://doi.org/10.3233/JAD-2009-1051
82. Holsinger RMD, Schnarr J, Henry P, et al (2000) Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: Decreased levels in Alzheimer’s disease. Molecular Brain Research 76:347–354. https://doi.org/10.1016/S0169-328X(00)00023-1
83. Peng S, Wuu J, Mufson EJ, Fahnestock M (2005) Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. Journal of Neurochemistry 93:1412–1421. https://doi.org/10.1111/j.1471-4159.2005.03135.x
84. Lue LF, Kuo YM, Roher AE, et al (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. The American journal of pathology 155:853–862. https://doi.org/10.1016/s0002-9440(10)65184-x
85. McLean CA, Cherny RA, Fraser FW, et al (1999) Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Annals of Neurology 46:860–866. https://doi.org/10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M
86. Carrasquillo MM, Belbin O, Zou F, et al (2010) Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer’s disease. PloS one 5:e8764. https://doi.org/10.1371/journal.pone.0008764
87. Kilger E, Buehler A, Woelfing H, et al (2011) BRI2 protein regulates β-amyloid degradation by increasing levels of secreted insulin-degrading enzyme (IDE). Journal of Biological Chemistry 286:37446–37457. https://doi.org/10.1074/jbc.M111.288373
88. Liu XP, Qian X, Xie Y, et al (2014) Betaine suppressed Aβ generation by altering amyloid precursor protein processing. Neurological Sciences 35:1009–1013. https://doi.org/10.1007/s10072-014-1630-y
89. Probst A, Botez G, Tolnay M (1999) [Neuropathological aspects of Alzheimer disease]. Therapeutische Umschau Revue therapeutique 56:88–93. https://doi.org/10.1024/0040-5930.56.2.88
90. Giannakopoulos P, Kövari E, Gold G, et al (2009) Pathological substrates of cognitive decline in alzheimer’s disease. Frontiers of Neurology and Neuroscience 24:20–29. https://doi.org/10.1159/000197881
91. Pooler AM, Noble W, Hanger DP (2014) A role for tau at the synapse in Alzheimer’s disease pathogenesis. Neuropharmacology 76:1–8. https://doi.org/10.1016/j.neuropharm.2013.09.018
92. Ferrer I (2004) Stress kinases involved in Tau phosphorylation in Alzheimer’s disease, tauopathies and APP transgenic mice. Neurotoxicity Research 6:469–475. https://doi.org/10.1007/BF03033283
93. Chauhan NB, Siegel GJ, Feinstein DL (2005) Propentofylline attenuates tau hyperphosphorylation in Alzheimer’s Swedish mutant model Tg2576. Neuropharmacology 48:93–104. https://doi.org/10.1016/j.neuropharm.2004.09.014
94. Ferrer I, Gomez-Isla T, Puig B, et al (2005) Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer’s disease and tauopathies. Current Alzheimer research 2:3–18. https://doi.org/10.2174/1567205052772713
95. Milligan G, Shimpukade B, Ulven T, Hudson BD (2017) Complex Pharmacology of Free Fatty Acid Receptors. Chemical reviews 117:67–110. https://doi.org/10.1021/acs.chemrev.6b00056
96. Milligan G, Bolognini D, Sergeev E (2017) Ligands at the Free Fatty Acid Receptors 2/3 (GPR43/GPR41). Handbook of experimental pharmacology 236:17–32. https://doi.org/10.1007/164_2016_49
97. Hudson BD, Ulven T, Milligan G (2013) The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. Current topics in medicinal chemistry 13:14–25. https://doi.org/10.2174/1568026611313010004
98. Grundmann M, Bender E, Schamberger J, Eitner F (2021) Pharmacology of free fatty acid receptors and their allosteric modulators. International Journal of Molecular Sciences 22:1–38. https://doi.org/10.3390/ijms22041763.
99. Milligan G, Stoddart LA, Smith NJ (2009) Agonism and allosterism: The pharmacology of the free fatty acid receptors FFA2 and FFA3. British Journal of Pharmacology 158:146–153. https://doi.org/10.1111/j.1476-5381.2009.00421.x.
100. Watterson KR, Hudson BD, Ulven T, Milligan G (2014) Treatment of type 2 diabetes by free Fatty Acid receptor agonists. Frontiers in endocrinology 5:137. https://doi.org/10.3389/fendo.2014.00137
101. Lonsdale J, Thomas J, Salvatore M, et al (2013) The Genotype-Tissue Expression (GTEx) project. Nature Genetics 45:580–585. https://doi.org/10.1038/ng.2653.